SCHEMBL4143702

SCHEMBL4143702

Cc1cc(=O)n(CCc2ccccc2)c(-c2ccccc2)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 6/20 0.70
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HSD17B10 Q99714 4/20 0.47
KDM4E B2RXH2 3/20 0.47
RAB9A P51151 3/20 0.47
MAPT P10636 2/20 0.47
TSHR P16473 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
LMNA P02545 2/20 0.44
PLA2G1B P04054 1/20 0.44
GAA P10253 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
NOX4 Q9NPH5 1/20 0.44
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5098015 0.88 CASR (0.57) CASRMEN1KMT2AHSD17B10RAB9A
SCHEMBL3380715 0.82 CASR (1.00) CASR
SCHEMBL13851579 0.81 CASR (0.61) CASRMEN1KMT2AHSD17B10KDM4E
SCHEMBL27751196 0.81 CASR (0.72) CASRMEN1KMT2AHSD17B10KDM4E
SCHEMBL28777939 0.81 CASR (0.49) CASRHSD17B10KDM4ERAB9AALDH1A1
SCHEMBL4151611 0.80 CASR (0.70) CASRMEN1KMT2AKDM4ERAB9A
SCHEMBL4143491 0.79 CASR (0.67) CASRMEN1KMT2ATSHRALDH1A1
SCHEMBL4147460 0.78 CASR (0.73) CASR
SCHEMBL4153000 0.77 CASR (0.66) CASRMEN1KMT2AHSD17B10KDM4E
SCHEMBL4145041 0.76 CASR (0.64) CASRTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
CN-101360498-A Calcilytic compounds SMITHKLINE BEECHAM CORP (US) 2009-02-04 CN disclosed
EP-1951244-A2 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB CASR 12/4885MEN1 145/4885KMT2A 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.